Fresh analysis indicates that people who stop using popular weight-loss injections like Mounjaro or Wegovy tend to recover lost weight far faster than those who halt conventional diet and exercise regimens.
Research printed in a prominent medical journal shows that while overweight people can lose substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such drugs must be aware of the risk of quick weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass within about 18 months.
Analyzing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.
Scientists point out that individuals who lose weight through diet and exercise generally experience a slower weight regain—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Nutrition scientists propose the way of the injections accounts for the amplified weight return.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making overeating much more probable."
A Lifelong Disease?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals argue that, given the significant potential of weight regain, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who note that the results "emphasize the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have come off the medication explain a intense return of hunger.
"I experienced something that goes on and you become ravenous," described one woman.
This challenge is compounded if users have not developed permanent dietary or behavioural changes during treatment.
Significant Use
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is greater among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on combined lifestyle support.
